Patents Assigned to UCB Pharma Limited
  • Non-toxic double mutant forms of pertussis toxin as adjuvants
    Publication number: 20100255033
    Abstract: The invention relates to the use of an antigen which is a non-toxic double mutant form of pertussis toxin for the manufacture of a vaccine composition for intranasal administration to induce an immune response against B. pertussis infection. The invention also relates to the use of a non-toxic double mutant form of pertussis toxin for the manufacture of an adjuvant composition for stimulating or enhancing a protective immune response of an antigen co-administered therewith. The non-toxic double mutant is preferably one in which the glutamic acid 129 amino acid in the S1 sub-unit has been substituted by glycine and the arginine 9 amino acid has been substituted by lysine.
    Type: Application
    Filed: January 9, 2007
    Publication date: October 7, 2010
    Applicant: UCB Pharma Limited
    Inventor: Mark Roberts
  • Acellular vaccine comprising a combination of the 69 kDa and the filamentous haemagglutinin antigens of
    Patent number: 7479283
    Abstract: An acellular vaccine is provided which in use provides protection against Bordetella pertussis infections. The vaccine is based on the synergistic combination of two antigenes from B. pertussis, the 69 kDa, and the filamentous haemagglutinin antigens.
    Type: Grant
    Filed: May 25, 1995
    Date of Patent: January 20, 2009
    Assignee: UCB Pharma Limited
    Inventor: Pavel Novotny
  • Non-toxic double mutant forms of pertussis toxin as adjuvants
    Patent number: 7169399
    Abstract: The invention relates to the use of an antigen which is a non-toxic double mutant form of pertussis toxin for the manufacture of a vaccine composition for intranasal administration to induce an immune response against B. pertussis infection. The invention also relates to the use of a non-toxic double mutant form of pertussis toxin for the manufacture of an adjuvant composition for stimulating or enhancing a protective immune response of an antigen co-administered therewith. The non-toxic double mutant is preferably one in which the glutamic acid 129 amino acid in the S1 sub-unit has been substituted by glycine and the arginine 9 amino acid has been substituted by lysine.
    Type: Grant
    Filed: February 2, 2001
    Date of Patent: January 30, 2007
    Assignee: UCB Pharma Limited
    Inventor: Mark Roberts